Pharmacologic Support of Critically ill Patients
Cardiovascular collapse is a devastating clinical entity frequently observed in both medical and surgical intensive care unit patients. Despite the gravity of this condition, advances in cardiovascular physiology, molecular biology, and pharmacology, now allow physicians to offer rational therapeutic interventions to such patients. This chapter will review the basic pathophysiology of cardiac failure, identify cellular targets for pharmacologic intervention, and discuss the actions and uses of some of the newer inotropic agents.
KeywordsPhosphodiesterase Inhibitor Inotropic Agent High Risk Surgical Patient Inotropic Therapy Surgical Intensive Care Unit Patient
Unable to display preview. Download preview PDF.
- 1.Shore-Lesserson L, Konstadt S (1994) Recent advances in cardiac pharmacology. Anesth Clin North Am 12:133–168.Google Scholar
- 4.Feldman MD, Copelas L, Gwathmey JK, Phillips SP, Warren SE, Schoen FJ, Grossman W, Morgan JP (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75:331–339.PubMedCrossRefGoogle Scholar
- 7.Boyd O, Lamb G, Mackey CJ, Grounds RM, Bennett ED (1995) A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Anasth & Int Care 23:478–484.Google Scholar
- Remme WJ(1993) Ino dilator therapy for heart failure. Early, late, or not at all? Circulation 87 (5 Suppl):IV97–107.Google Scholar
- 20.Novitzky D, Cooper DKC, Barton CI, Greer A, Chaffin J, Grim J, Zuhid N (1989) Triiodothyronine as an inotropic agent after open heart surgery. J Thorc Cardiovasc Surg 98:972–978.Google Scholar